The Resource Cost of Switching Stable Rheumatology Patients From An Originator Biologic To A Biosimilar In The UK
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.821
https://www.valueinhealthjournal.com/article/S1098-3015(17)31155-5/fulltext
Section Title :
Disease-Specific Studies
Section Order :
779
First Page :
A543
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31155-5&doi=10.1016/j.jval.2017.08.821